Novel dry powder inhaler formulation containing antibiotic using combined technology to improve aerodynamic properties

Rita Ambrus, Edit Benke, Árpád Farkas, I. Balásházy, P. Szabó-Révész

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Dry Powder Inhaler (DPI) could offer a propellant-free, easy-to-use powder form ensuring better stability than liquid dosage forms. Therefore the development of traditional carrier-based and carrier-free new generation systems is a determinative factor in the field of DPI formulation. The purpose of our research work was to combine these two systems, utilizing their beneficial properties to produce a novel pulmonary drug delivery system containing ciprofloxacin hydrochloride (CIP). Co-spray drying, surface smoothing and the preparation of an interactive physical mixture were applied as the technological procedures of sample preparation. The carrier-based and carrier-free formulations, as well as the developed novel product were compared to each other. Structural investigations were made by X-ray powder diffraction and micrometric properties (habit, bulk density) were determined. Particle interactions were also evaluated to investigate surface free energy, cohesive-adhesive forces, and spreading coefficient. In vitro aerodynamic properties (mass median aerodynamic diameter), fine particle fraction (FPF) and emitted dose of DPIs were measured using Andersen Cascade Impactor. A novel in silico Stochastic Lung Model was also used to quantify the amount of particles deposited at the target area. The novel-formulated composition presented amorphous spherical particles with an average size of about 2 μm. The in vitro aerodynamic investigations showed a variance in FPF as a function of formulation method (carrier-based: 24%, carrier-free: 54% and applying the novel combination method: 63%). The in silico deposition results were in line with the in vitro measurements and yielded increased lung doses for the sample prepared by the combined technology. This novel DPI formulation provides an opportunity for a more effective therapy with deeper deposition of CIP.

Original languageEnglish
Pages (from-to)20-27
Number of pages8
JournalEuropean Journal of Pharmaceutical Sciences
Volume123
DOIs
Publication statusPublished - Oct 15 2018

Fingerprint

Dry Powder Inhalers
Ciprofloxacin
Anti-Bacterial Agents
Technology
Computer Simulation
Lung
Powder Diffraction
Dosage Forms
Drug Delivery Systems
X-Ray Diffraction
Adhesives
Powders
Habits
Research
In Vitro Techniques
Therapeutics

Keywords

  • Aerosolization efficiency
  • Ciprofloxacin hydrochloride
  • Combined technologies
  • DPI formulation
  • In silico numerical model
  • Interparticle interaction

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Novel dry powder inhaler formulation containing antibiotic using combined technology to improve aerodynamic properties. / Ambrus, Rita; Benke, Edit; Farkas, Árpád; Balásházy, I.; Szabó-Révész, P.

In: European Journal of Pharmaceutical Sciences, Vol. 123, 15.10.2018, p. 20-27.

Research output: Contribution to journalArticle

@article{e644dc712e4c48cb8146a01a1551ba18,
title = "Novel dry powder inhaler formulation containing antibiotic using combined technology to improve aerodynamic properties",
abstract = "Dry Powder Inhaler (DPI) could offer a propellant-free, easy-to-use powder form ensuring better stability than liquid dosage forms. Therefore the development of traditional carrier-based and carrier-free new generation systems is a determinative factor in the field of DPI formulation. The purpose of our research work was to combine these two systems, utilizing their beneficial properties to produce a novel pulmonary drug delivery system containing ciprofloxacin hydrochloride (CIP). Co-spray drying, surface smoothing and the preparation of an interactive physical mixture were applied as the technological procedures of sample preparation. The carrier-based and carrier-free formulations, as well as the developed novel product were compared to each other. Structural investigations were made by X-ray powder diffraction and micrometric properties (habit, bulk density) were determined. Particle interactions were also evaluated to investigate surface free energy, cohesive-adhesive forces, and spreading coefficient. In vitro aerodynamic properties (mass median aerodynamic diameter), fine particle fraction (FPF) and emitted dose of DPIs were measured using Andersen Cascade Impactor. A novel in silico Stochastic Lung Model was also used to quantify the amount of particles deposited at the target area. The novel-formulated composition presented amorphous spherical particles with an average size of about 2 μm. The in vitro aerodynamic investigations showed a variance in FPF as a function of formulation method (carrier-based: 24{\%}, carrier-free: 54{\%} and applying the novel combination method: 63{\%}). The in silico deposition results were in line with the in vitro measurements and yielded increased lung doses for the sample prepared by the combined technology. This novel DPI formulation provides an opportunity for a more effective therapy with deeper deposition of CIP.",
keywords = "Aerosolization efficiency, Ciprofloxacin hydrochloride, Combined technologies, DPI formulation, In silico numerical model, Interparticle interaction",
author = "Rita Ambrus and Edit Benke and {\'A}rp{\'a}d Farkas and I. Bal{\'a}sh{\'a}zy and P. Szab{\'o}-R{\'e}v{\'e}sz",
year = "2018",
month = "10",
day = "15",
doi = "10.1016/j.ejps.2018.07.030",
language = "English",
volume = "123",
pages = "20--27",
journal = "European Journal of Pharmaceutical Sciences",
issn = "0928-0987",
publisher = "Elsevier",

}

TY - JOUR

T1 - Novel dry powder inhaler formulation containing antibiotic using combined technology to improve aerodynamic properties

AU - Ambrus, Rita

AU - Benke, Edit

AU - Farkas, Árpád

AU - Balásházy, I.

AU - Szabó-Révész, P.

PY - 2018/10/15

Y1 - 2018/10/15

N2 - Dry Powder Inhaler (DPI) could offer a propellant-free, easy-to-use powder form ensuring better stability than liquid dosage forms. Therefore the development of traditional carrier-based and carrier-free new generation systems is a determinative factor in the field of DPI formulation. The purpose of our research work was to combine these two systems, utilizing their beneficial properties to produce a novel pulmonary drug delivery system containing ciprofloxacin hydrochloride (CIP). Co-spray drying, surface smoothing and the preparation of an interactive physical mixture were applied as the technological procedures of sample preparation. The carrier-based and carrier-free formulations, as well as the developed novel product were compared to each other. Structural investigations were made by X-ray powder diffraction and micrometric properties (habit, bulk density) were determined. Particle interactions were also evaluated to investigate surface free energy, cohesive-adhesive forces, and spreading coefficient. In vitro aerodynamic properties (mass median aerodynamic diameter), fine particle fraction (FPF) and emitted dose of DPIs were measured using Andersen Cascade Impactor. A novel in silico Stochastic Lung Model was also used to quantify the amount of particles deposited at the target area. The novel-formulated composition presented amorphous spherical particles with an average size of about 2 μm. The in vitro aerodynamic investigations showed a variance in FPF as a function of formulation method (carrier-based: 24%, carrier-free: 54% and applying the novel combination method: 63%). The in silico deposition results were in line with the in vitro measurements and yielded increased lung doses for the sample prepared by the combined technology. This novel DPI formulation provides an opportunity for a more effective therapy with deeper deposition of CIP.

AB - Dry Powder Inhaler (DPI) could offer a propellant-free, easy-to-use powder form ensuring better stability than liquid dosage forms. Therefore the development of traditional carrier-based and carrier-free new generation systems is a determinative factor in the field of DPI formulation. The purpose of our research work was to combine these two systems, utilizing their beneficial properties to produce a novel pulmonary drug delivery system containing ciprofloxacin hydrochloride (CIP). Co-spray drying, surface smoothing and the preparation of an interactive physical mixture were applied as the technological procedures of sample preparation. The carrier-based and carrier-free formulations, as well as the developed novel product were compared to each other. Structural investigations were made by X-ray powder diffraction and micrometric properties (habit, bulk density) were determined. Particle interactions were also evaluated to investigate surface free energy, cohesive-adhesive forces, and spreading coefficient. In vitro aerodynamic properties (mass median aerodynamic diameter), fine particle fraction (FPF) and emitted dose of DPIs were measured using Andersen Cascade Impactor. A novel in silico Stochastic Lung Model was also used to quantify the amount of particles deposited at the target area. The novel-formulated composition presented amorphous spherical particles with an average size of about 2 μm. The in vitro aerodynamic investigations showed a variance in FPF as a function of formulation method (carrier-based: 24%, carrier-free: 54% and applying the novel combination method: 63%). The in silico deposition results were in line with the in vitro measurements and yielded increased lung doses for the sample prepared by the combined technology. This novel DPI formulation provides an opportunity for a more effective therapy with deeper deposition of CIP.

KW - Aerosolization efficiency

KW - Ciprofloxacin hydrochloride

KW - Combined technologies

KW - DPI formulation

KW - In silico numerical model

KW - Interparticle interaction

UR - http://www.scopus.com/inward/record.url?scp=85049895220&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049895220&partnerID=8YFLogxK

U2 - 10.1016/j.ejps.2018.07.030

DO - 10.1016/j.ejps.2018.07.030

M3 - Article

VL - 123

SP - 20

EP - 27

JO - European Journal of Pharmaceutical Sciences

JF - European Journal of Pharmaceutical Sciences

SN - 0928-0987

ER -